Back to List View Graph View

Cluster of Differentiation 19 (CD19)

CD19 is a transmembrane protein that plays a crucial role in the development and activation of B cells, a type of white blood cell integral to the immune response.

Where the papers sit

25 papers from the last 6 months study Cluster of Differentiation 19 (CD19) directly · updated from PubMed 16 Nov 2026

  • CD19 CAR-T Resistance

    Antigen density and CD19 loss are emerging as major determinants of CAR-T failure in large B-cell lymphoma. RHOA deletion links reduced CD19 expression to dysfunctional immune microenvironments and poorer response. Clinical work continues to relate tumor antigen levels, fludarabine exposure and progression-free survival after axicabtagene ciloleucel or other CD19 CAR-T products. Multiplex engineering and redesigned binding domains aim to restore activity against antigen-low or resistant disease.

    10 papers · 40%

  • B-ALL Immunotherapy

    CD19-directed therapy is moving toward chemotherapy-sparing treatment and definitive consolidation in B-cell acute lymphoblastic leukemia. Blinatumomab is being tested as a bridge to transplant or replacement for chemotherapy, while CAR-T therapy is being compared with it in relapsed disease and used earlier in older adults. Cytokine release syndrome and immune effector cell-associated neurotoxicity remain important limitations, including severe blinatumomab-associated cerebral edema. Pediatric CART22.19 and selected nonmalignant applications broaden the field but remain early.

    7 papers · 28%

  • CD19 Cell Therapy in Autoimmunity

    CD19-directed cellular therapy is being developed as an immune-reset strategy for refractory systemic lupus erythematosus, lupus nephritis and myasthenia gravis. Allogeneic CD19 CAR-NK cells offer a potentially lower-intensity alternative, with low-dose cord-blood products and 4-1BB co-stimulation under early evaluation. CAR-T case series report durable clinical improvement in myasthenia gravis, while lupus studies are still defining safety, disease remission and durability. Controlled trials are needed to establish whether deep B-cell depletion can replace chronic immunosuppression.

    5 papers · 20%

  • Multitarget CAR-T Therapy

    Single-antigen targeting is giving way to trispecific CAR-T cells directed against CD19, CD20 and CD22 in lymphoma. Point-of-care manufacturing and early first-in-human data are testing whether broader antigen coverage improves clinical activity without unacceptable inflammatory toxicity. The recurring concern is functional T-cell state, including differentiation and exhaustion, as well as antigen transfer between B cells and other immune cells. Whether multispecific designs prevent relapse remains open.

    3 papers · 12%

NEW DIRECTION

CD19 can function as a transferable immune-cell program rather than merely a B-cell lineage marker

The mouse and human B-cell–T-cell co-culture and experimental autoimmune encephalomyelitis study found that activated B cells transfer CD19 by trogocytosis to T cells, which acquire enhanced activation and encephalitogenic features, while myeloid cells acquire CD19, functional IgM, and B-cell-like properties after phagocytosing apoptotic B cells 42527393Jul. This assigns CD19 a role beyond identifying or targeting B cells: it can be a mobile component associated with functional reprogramming of other immune-cell types, complicating assumptions about cellular specificity and the selectivity of anti-CD19 therapy.

Papers

The 25 papers from the last 6 months that study Cluster of Differentiation 19 (CD19) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

CD19 CAR-T Resistance (10)
  1. CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after All. Blood cancer discovery · 12 Oct 2026 PMID 42862024
  2. Reviving low-affinity glycan-targeting CAR with combinatorial design. Cell reports. Medicine · 8 Oct 2026 PMID 42849448
  3. RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR T-Resistant Large B-cell Lymphomas. Blood cancer discovery · 18 Sept 2026 PMID 42757854
  4. Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma. Blood cancer discovery · 31 Aug 2026 PMID 42671910
  5. A Generalization of the Ternary Binding Model to Membrane-Confined Systems With Finite Copy Number. CPT: pharmacometrics & systems pharmacology · 28 Aug 2026 PMID 42663854
  6. CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study. The Lancet. Haematology · 27 Aug 2026 PMID 42660131
  7. A singular base-editing platform for polyfunctional multiplex engineering of immune cells. Molecular therapy : the journal of the American Society of Gene Therapy · 18 Jul 2026 PMID 42470099
  8. Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight. Hematological oncology · 24 Jun 2026 PMID 42339679
  9. Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma. Blood advances · 10 Jun 2026 PMID 42269079
  10. Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy. Science advances · 10 Jun 2026 PMID 42268944
B-ALL Immunotherapy (7)
  1. Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL. Journal for immunotherapy of cancer · 28 Sept 2026 PMID 42805761
  2. Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia. The New England journal of medicine · 16 Sept 2026 PMID 42748428
  3. Blinatumomab-induced catastrophic immune effector cell-associated neurotoxicity with diffuse cerebral edema in a patient with ALL: Case report. International journal of clinical pharmacology and therapeutics · 25 Aug 2026 PMID 42638547
  4. CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission. Blood advances · 24 Jun 2026 PMID 42341322
  5. Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation. Clinical lymphoma, myeloma & leukemia · 11 Jun 2026 PMID 42276849
  6. CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial. Blood · 27 May 2026 PMID 42201777
  7. Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort. Journal for immunotherapy of cancer · 21 May 2026 PMID 42167809
CD19 Cell Therapy in Autoimmunity (5)
  1. Generalized myasthenia gravis: Clinical trials to watch. Med (New York, N.Y.) · 11 Sept 2026 PMID 42727567
  2. Allogeneic CD19 CAR-NK cell therapy for a patient with relapsed and refractory lupus nephritis. Arthritis research & therapy · 9 Sept 2026 PMID 42711699
  3. Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series. Cell reports. Medicine · 21 Aug 2026 PMID 42628528
  4. Gone but not forgotten: CAR-NK cells leave a lasting mark on autoimmunity. Med (New York, N.Y.) · 14 Aug 2026 PMID 42600571
  5. Safety and efficacy of low-dose, cord blood-derived CD19 CAR-NK cells with 4-1BB co-stimulation in refractory systemic lupus erythematosus. Med (New York, N.Y.) · 22 Jul 2026 PMID 42486100
Multitarget CAR-T Therapy (3)
  1. Hattrick against Lymphoma with Trispecific CAR T Cells. Blood cancer discovery · 10 Aug 2026 PMID 42573282
  2. B cell CD19 is transferred between immune cells in mice and humans. Nature communications · 29 Jul 2026 PMID 42527393
  3. Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22. Blood cancer discovery · 14 Jul 2026 PMID 42446920

By study type

Clinical trials (6)
  1. Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia. The New England journal of medicine · 16 Sept 2026 PMID 42748428
  2. CD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study. The Lancet. Haematology · 27 Aug 2026 PMID 42660131
  3. Safety and efficacy of low-dose, cord blood-derived CD19 CAR-NK cells with 4-1BB co-stimulation in refractory systemic lupus erythematosus. Med (New York, N.Y.) · 22 Jul 2026 PMID 42486100
  4. Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22. Blood cancer discovery · 14 Jul 2026 PMID 42446920
  5. CAR T-cell therapy as a definitive consolidation for older adults with B-ALL in first complete remission. Blood advances · 24 Jun 2026 PMID 42341322
  6. CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial. Blood · 27 May 2026 PMID 42201777
Observational studies and case reports (8)
  1. Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL. Journal for immunotherapy of cancer · 28 Sept 2026 PMID 42805761
  2. Allogeneic CD19 CAR-NK cell therapy for a patient with relapsed and refractory lupus nephritis. Arthritis research & therapy · 9 Sept 2026 PMID 42711699
  3. Blinatumomab-induced catastrophic immune effector cell-associated neurotoxicity with diffuse cerebral edema in a patient with ALL: Case report. International journal of clinical pharmacology and therapeutics · 25 Aug 2026 PMID 42638547
  4. Long-term outcomes of anti-CD19 CAR T cell therapy in refractory myasthenia gravis: A case series. Cell reports. Medicine · 21 Aug 2026 PMID 42628528
  5. Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight. Hematological oncology · 24 Jun 2026 PMID 42339679
  6. Pretransplant Blinatumomab Is Associated With Reduced Relapse and Improved Disease-Free Survival in Adults With B-Cell ALL Undergoing Allogeneic Hematopoietic Cell Transplantation. Clinical lymphoma, myeloma & leukemia · 11 Jun 2026 PMID 42276849
  7. Impact of fludarabine exposure on CAR T-cell outcomes in patients with large B-cell lymphoma. Blood advances · 10 Jun 2026 PMID 42269079
  8. Human CART22.19 therapy in refractory pediatric B-ALL: insights from a named-patient cohort. Journal for immunotherapy of cancer · 21 May 2026 PMID 42167809
Human data, design not indexed (7)
  1. CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after All. Blood cancer discovery · 12 Oct 2026 PMID 42862024
  2. Generalized myasthenia gravis: Clinical trials to watch. Med (New York, N.Y.) · 11 Sept 2026 PMID 42727567
  3. Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma. Blood cancer discovery · 31 Aug 2026 PMID 42671910
  4. A Generalization of the Ternary Binding Model to Membrane-Confined Systems With Finite Copy Number. CPT: pharmacometrics & systems pharmacology · 28 Aug 2026 PMID 42663854
  5. Gone but not forgotten: CAR-NK cells leave a lasting mark on autoimmunity. Med (New York, N.Y.) · 14 Aug 2026 PMID 42600571
  6. Hattrick against Lymphoma with Trispecific CAR T Cells. Blood cancer discovery · 10 Aug 2026 PMID 42573282
  7. A singular base-editing platform for polyfunctional multiplex engineering of immune cells. Molecular therapy : the journal of the American Society of Gene Therapy · 18 Jul 2026 PMID 42470099
Preclinical: animal, cell and lab studies (4)
  1. Reviving low-affinity glycan-targeting CAR with combinatorial design. Cell reports. Medicine · 8 Oct 2026 PMID 42849448
  2. RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR T-Resistant Large B-cell Lymphomas. Blood cancer discovery · 18 Sept 2026 PMID 42757854
  3. B cell CD19 is transferred between immune cells in mice and humans. Nature communications · 29 Jul 2026 PMID 42527393
  4. Ultrasound priming gated by solid tumor hallmarks to guide CAR-T therapy. Science advances · 10 Jun 2026 PMID 42268944